Contraindications for Methergine and Carboprost in Postpartum Hemorrhage Management
Methergine (Methylergonovine) Contraindications
Methylergonovine is absolutely contraindicated in hypertensive patients due to its vasoconstrictive properties that can precipitate dangerous blood pressure elevations. 1, 2
Absolute Contraindications:
- Hypertension or preeclampsia - The drug causes vasoconstriction with >10% risk of hypertensive crisis 2
- Active cardiovascular disease - Particularly when increased pulmonary artery pressure would be harmful 2
- Peripheral vascular disease - Due to vasoconstrictive effects 1
Clinical Context:
Methylergonovine is positioned as a second-line agent after oxytocin failure, with a dose of 0.2 mg IM 1. Despite the contraindication in hypertensive patients, methylergonovine demonstrates superior efficacy compared to carboprost in reducing hemorrhage-related morbidity (relative risk 0.59; 95% CI 0.38-0.83) in appropriate candidates 3.
Carboprost Contraindications
Carboprost has fewer absolute contraindications than methylergonovine, but requires caution in specific cardiopulmonary conditions.
Absolute Contraindications per FDA Label:
- Active pelvic inflammatory disease - Risk of exacerbating infection 4
- Active cardiac, pulmonary, renal, or hepatic disease - The FDA label emphasizes careful evaluation in these conditions 4
Relative Contraindications and Special Considerations:
- Asthma or reactive airway disease - Prostaglandins can cause bronchospasm 4
- Chorioamnionitis - May have inhibitory effect on uterine response; 3 of 8 patients (37.5%) with chorioamnionitis failed to respond to carboprost in clinical trials 4
Expected Side Effects (Not Contraindications):
- Transient pyrexia - Temperature elevations exceeding 2°F (1.1°C) occur in approximately 12.5% of patients, typically within 1-16 hours of injection and self-limiting 4
- Moderate hypertension - Occurred in 5/115 (4%) of postpartum hemorrhage cases, though causality uncertain and no specific therapy required 4
Critical Clinical Algorithm for Drug Selection
Step 1: First-Line Management
- Administer oxytocin 5-10 IU IV or IM with uterine massage 1
- Add tranexamic acid 1g IV over 10 minutes if within 3 hours of birth 1, 2
Step 2: Second-Line Selection Based on Patient Characteristics
If patient is HYPERTENSIVE or has cardiovascular disease:
- Choose carboprost (methylergonovine absolutely contraindicated) 1, 2
- Dose: 250 mcg IM, may repeat every 15-90 minutes (maximum 8 doses) 4
If patient is NORMOTENSIVE without active pulmonary disease:
- Prefer methylergonovine (superior efficacy data) 3
- Dose: 0.2 mg IM 1
- Methylergonovine reduces hemorrhage-related morbidity by 41% compared to carboprost 3
If patient has ASTHMA or active pulmonary disease:
- Avoid carboprost (risk of bronchospasm) 4
- Use methylergonovine if normotensive, or proceed to mechanical interventions 1
If patient has CHORIOAMNIONITIS:
- Anticipate reduced response to carboprost (37.5% failure rate) 4
- Consider earlier escalation to mechanical interventions 4
Common Pitfalls to Avoid
Timing Errors:
- Do not delay carboprost administration while waiting for laboratory results in active hemorrhage 1
- Do not administer tranexamic acid beyond 3 hours postpartum - it becomes contraindicated and potentially harmful 1, 2, 5
Drug Interaction:
- Do not combine methylergonovine and carboprost with other oxytocic agents simultaneously - carboprost may augment activity of other oxytocics unpredictably 4
Misdiagnosis of Fever:
- Drug-induced pyrexia from carboprost occurs within 1-16 hours, is self-limiting, and does not require antibiotics 4
- Endometritis typically presents on postpartum day 3 with foul-smelling lochia, uterine tenderness, and retained products 4
- The key distinction: carboprost-induced fever resolves spontaneously after discontinuation without treatment; endometritis requires antibiotics 4